Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.59 |
| ▸ | CTSK | P43235 | 8/20 | 0.56 |
| ▸ | CTSS | P25774 | 5/20 | 0.55 |
| ▸ | CTSL | P07711 | 3/20 | 0.55 |
| ▸ | CTSB | P07858 | 2/20 | 0.55 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.54 |
| ▸ | PPARA | Q07869 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | TACR1 | P25103 | 2/20 | 0.50 |
| ▸ | KYNU | Q16719 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6320951 | 1.00 | SYK (0.59) | SYKCTSKCTSSCTSLCTSB | |
| SCHEMBL4641124 | 1.00 | SYK (0.59) | SYKCTSKCTSSCTSLCTSB | |
| SCHEMBL376154 | 0.90 | SYK (0.57) | SYKCTSKCTSSCTSLCTSB | |
| SCHEMBL995705 | 0.90 | SYK (0.57) | SYKCTSKCTSSCTSLCTSB | |
| SCHEMBL2619553 | 0.90 | SYK (0.57) | SYKCTSKCTSSCTSLCTSB | |
| SCHEMBL1562695 | 0.89 | PPARA (0.59) | SYKCTSKCTSSCTSLCTSB | |
| SCHEMBL7172323 | 0.89 | PPARA (0.59) | SYKCTSKCTSSCTSLCTSB | |
| SCHEMBL19485480 | 0.89 | CTSK (0.62) | SYKCTSKCTSSCTSLCTSB | |
| SCHEMBL21340066 | 0.89 | SYK (0.66) | SYKCTSKCTSSCTSLCTSB | |
| SCHEMBL13688643 | 0.89 | SYK (0.66) | SYKCTSKCTSSCTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025151608-A1 | CONNECTING UNITS FOR LIGAND-DRUG CONJUGATES AND METHODS OF MAKING AND USING THEREOF | SYSTIMMUNE, INC. (US) | 2025-07-17 | — | — | WO | disclosed |
| EP-4552498-A1 | METHOD FOR PREVENTING INSECT DAMAGE TO PLANTS | AJINOMOTO CO., INC. (JP) | 2025-05-14 | — | — | EP | disclosed |
| US-12286455-B2 | Anthelmintic depsipeptide compounds | Boehringer Ingelheim Animal Health USA Inc. (US) | 2025-04-29 | — | — | US | disclosed |
| US-20250127166-A1 | METHOD FOR PREVENTING INSECT DAMAGE TO PLANTS | AJINOMOTO CO., INC. (JP) | 2025-04-24 | — | — | US | disclosed |
| CN-118255684-B | CD4 enhancement+Compounds for T cell differentiation into Th9 cells | 广州医科大学 | 2025-03-07 | — | — | CN | disclosed |
| CN-118255684-A | CD4 enhancement+Compounds for T cell differentiation into Th9 cells | 广州医科大学 | 2024-06-28 | — | — | CN | disclosed |
| WO-2024010005-A1 | METHOD FOR PREVENTING INSECT DAMAGE TO PLANTS | 味の素株式会社 | 2024-01-11 | — | — | WO | disclosed |
| US-11382949-B2 | Anthelmintic depsipeptide compounds | Boehringer Ingelheim Animal Health USA Inc. (US) | 2022-07-12 | — | — | US | disclosed |
| US-11382949-B2 | Anthelmintic depsipeptide compounds | Boehringer Ingelheim Animal Health USA Inc. (US) | 2022-07-12 | — | — | US | disclosed |
| US-10793604-B2 | Anthelmintic depsipeptide compounds | Boehringer Ingelheim Animal Health USA Inc. (US) | 2020-10-06 | — | — | US | disclosed |
| EP-1210348-A1 | NAPHTHYRIDINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | Aventis Pharma Deutschland GmbH (DE) | 2002-06-05 | — | — | EP | disclosed |
| EP-1196416-A1 | SUBSTITUTED PURINE DERIVATIVES AS INHIBITORS OF CELL ADHESION | Aventis Pharma Deutschland GmbH (DE) | 2002-04-17 | — | — | EP | disclosed |
| WO-2001002399-A1 | SUBSTITUTED PURINE DERIVATIVES AS INHIBITORS OF CELL ADHESION | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-01-11 | — | — | WO | disclosed |
| WO-2001002398-A1 | NAPHTHYRIDINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-01-11 | — | — | WO | disclosed |
| EP-1065208-A1 | Substituted purine derivatives as inhibitors of cell adhesion | Aventis Pharma Deutschland GmbH (DE) | 2001-01-03 | — | — | EP | disclosed |
| EP-1065207-A1 | Naphthyridine derivatives, processes for their preparation, their use, and pharmaceutical compositions comprising them | Aventis Pharma Deutschland GmbH (DE) | 2001-01-03 | — | — | EP | disclosed |
| CN-1193623-A | Substituted purine derivatives, their preparation, their use and compositions containing them | HOECHST AG (DE) | 1998-09-23 | — | — | CN | disclosed |
| EP-0853084-A2 | Substituted purine derivatives as vitronectin receptor antagonists | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-07-15 | — | — | EP | disclosed |
| EP-0518675-A2 | Cyclic renin inhibitors | MERCK & CO. INC. (US) | 1992-12-16 | — | — | EP | disclosed |
| EP-0431972-A2 | Macrocyclic lactones having renin inhibiting properties | MERCK & CO. INC. (US) | 1991-06-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11382949-B2 | Anthelmintic depsipeptide compounds | ENPP2, ROCK2, RRP12 | SYK 1165/4885CTSK 1247/4885CTSS 548/4885 |
| US-20250127166-A1 | METHOD FOR PREVENTING INSECT DAMAGE TO PLANTS | GGT1, GGH, CAT | SYK 4716/4885CTSK 886/4885CTSS 1745/4885 |
| US-10793604-B2 | Anthelmintic depsipeptide compounds | VIP, PREP, DNPEP | SYK 3404/4885CTSK 204/4885CTSS 245/4885 |
| US-12286455-B2 | Anthelmintic depsipeptide compounds | VIP, PREP, DNPEP | SYK 3404/4885CTSK 204/4885CTSS 245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.